Eyenovia, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic technology company that develops and commercializes advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform; the Optejet utilizes microdose array print (MAP) technology for precise, low-volume horizontal delivery to improve patient compliance, reduce waste, and enhance tolerability over traditional eye droppers. The company's core commercial portfolio includes Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic solution) for pharmacologic mydriasis (pupil dilation) during eye exams, following U.S. FDA approval in 2023 and commercial launch in 2024; clobetasol propionate ophthalmic suspension for post-ocular surgery pain and inflammation, with commercial launch pending; and pipeline candidates such as MicroPine (low-dose atropine ophthalmic solution) for slowing progressive myopia in pediatric patients, MicroLine for near vision improvement in presbyopia, and product candidates targeting elevated intraocular pressure related to conditions including primary angle-closure glaucoma, open-angle glaucoma, and ocular hypertension. Founded in 2014 and headquartered in New York, NY, with manufacturing operations in Reno, NV, Eyenovia primarily serves ophthalmologists, optometrists, and patients in the U.S. market while pursuing partnerships internationally, including with Arctic Vision in China and Korea for licensed products. Recent developments include ongoing negotiations toward a binding merger agreement with Betaliq, a clinical-stage glaucoma-focused company, following a signed letter of intent, with the exclusivity period extended to June 7, 2025 to finalize terms that would create a combined entity with complementary technologies and revenue from FDA-approved products; continued advancement of the user-filled Optejet device (UFD), on track for U.S. regulatory approval filing in September 2025 to enable direct consumer and practitioner use with user-selected medications such as OTC artificial tears; a corporate restructuring that reduced cash burn by approximately 70% year-over-year and strengthened the balance sheet as of Q1 2025; and a debt restructuring agreement with Avenue Capital deferring repayment obligations until October 2025.
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
Eyenovia Announces 1-for-80 Reverse Stock Split
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
Eyenovia Provides Update on Restructuring Efforts
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
Eyenovia to discontinue late-stage study for eye drug
Eyenovia Provides Update on Phase 3 CHAPERONE Study
Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates